Protease inhibitor with pharmacokinetic booster

This page covers all Protease inhibitor with pharmacokinetic booster drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting HIV protease.

Targets

HIV protease

Phase 3 pipeline (1)

• DRV/COBI FDC · Janssen Research & Development, LLC · Infectious Disease
  DRV/COBI is a fixed-dose combination of darunavir (a protease inhibitor) and cobicistat (a pharmacokinetic booster) that inhibits HIV protease to prevent viral replication.